SCHEMBL2108136

SCHEMBL2108136

COc1cccc(NC(=O)C(C(=O)Nc2ccccc2)c2ccc(C(=O)Nc3ccccc3N)cc2)c1

nearest known ligand 0.96

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 17/20 0.96
HDAC3 O15379 7/20 0.76
HDAC2 Q92769 7/20 0.76
HDAC4 P56524 2/20 0.59
HDAC7 Q8WUI4 2/20 0.59
HDAC10 Q969S8 2/20 0.59
HDAC11 Q96DB2 2/20 0.59
HDAC8 Q9BY41 2/20 0.59
HDAC6 Q9UBN7 2/20 0.59
HDAC9 Q9UKV0 2/20 0.59
HDAC5 Q9UQL6 2/20 0.59
EPHA2 P29317 1/20 0.57
NPC1 O15118 2/20 0.57
RAB9A P51151 2/20 0.57
NLRP3 Q96P20 1/20 0.57
NCOR2 Q9Y618 4/20 0.56
TRPV1 Q8NER1 1/20 0.56
ALDH1A1 P00352 1/20 0.54
TP53 P04637 1/20 0.54
PKM P14618 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1689052 0.98 HDAC1 (1.00) HDAC1HDAC3HDAC2HDAC4HDAC7
SCHEMBL1689291 0.91 HDAC1 (0.82) HDAC1HDAC3HDAC2HDAC4HDAC7
SCHEMBL1689265 0.88 HDAC1 (0.89) HDAC1HDAC3HDAC2HDAC4HDAC7
SCHEMBL1754325 0.87 HDAC1 (1.00) HDAC1HDAC3HDAC2NCOR2
SCHEMBL1689220 0.85 HDAC1 (0.76) HDAC1HDAC3HDAC2HDAC4HDAC7
SCHEMBL1689190 0.85 HDAC1 (0.74) HDAC1HDAC3HDAC2NCOR2
SCHEMBL1689184 0.85 HDAC1 (0.90) HDAC1HDAC3HDAC2NCOR2
SCHEMBL1689337 0.84 HDAC1 (0.96) HDAC1HDAC3HDAC2NCOR2
SCHEMBL1689210 0.82 HDAC1 (0.90) HDAC1HDAC3HDAC2NCOR2
SCHEMBL1689340 0.82 HDAC1 (0.74) HDAC1HDAC3HDAC2HDAC4HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1896395-B1 MODIFIED MALONATE DERIVATIVES MERCK SHARP & DOHME (US) 2015-07-15 EP claimed
US-8158825-B2 Modified malonate derivatives MERCK SHARP & DOHME CORP. (US) 2012-04-17 US claimed
US-20100160327-A1 Modified Malonate Derivatives MERCK SHARP & DOHME LLC 2010-06-24 US claimed
EP-1896395-B1 MODIFIED MALONATE DERIVATIVES MERCK SHARP & DOHME (US) 2015-07-15 EP disclosed
US-8158825-B2 Modified malonate derivatives MERCK SHARP & DOHME CORP. (US) 2012-04-17 US disclosed
US-20100160327-A1 Modified Malonate Derivatives MERCK SHARP & DOHME LLC 2010-06-24 US disclosed
EP-1896395-A2 MODIFIED MALONATE DERIVATIVES Merck & Co., Inc. (US) 2008-03-12 EP disclosed
WO-2007002248-A2 MODIFIED MALONATE DERIVATIVES MERCK & CO., INC. (US) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160327-A1 Modified Malonate Derivatives ME2, ME3, ME1 HDAC1 6/4885HDAC3 17/4885HDAC2 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.